Sanofi asks US court to halt diabetes drug patent fight with Mylan Medical Dialogues Bureau12 Feb 2020 10:30 AM IST In a stay application filed on Friday, Sanofi said a recent U.S. Court of Appeals for the Federal Circuit decision upholding the invalidation of two...
Overcharging on Anti-diabetic, Cardiac Care Drugs: Rs 245.96 crore recovered from Pharma Firms, Minister informs Parliament Farhat Nasim6 Feb 2020 4:43 PM ISTNPPA has detected and issued about 162 demand notices against the pharmaceutical companies for overcharging consumers on the sale of Anti-diabetic and...
Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M Medical Dialogues Bureau12 Dec 2019 11:53 AM ISTAhmedabad: With the Novartis Blockbuster Vildagliptin going off patent, Zydus Cadila has taken made its move towards affordable diabetes care in India...
Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio Farhat Nasim14 Oct 2019 1:36 PM ISTWhile two products Rivaroxaban and Vildagliptin will augment Morepen Lab's presence in the cardiac and diabetic segments respectively, the third...
AstraZeneca India bags DCGI marketing nod for QTERN-once-daily anti-diabetes drug Medical Dialogues Bureau27 Sept 2019 11:54 AM IST26 September 2019: AstraZeneca Pharma India Limited (AstraZeneca India) announced that it has received Import & Market permission for QTERN®...
Fight for Vildagliptin: Natco goes to court against Novartis Farhat Nasim7 Sept 2019 4:32 PM ISTMumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India Medical Dialogues Bureau5 Aug 2019 10:00 AM ISTSaroglitazar Magnesium was launched in India during September 2013, under the brand name 'Lipaglyn', for the treatment of hypertriglyceridemia and...
Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors Farhat Nasim30 July 2019 2:08 PM ISTNew Delhi: The patent protection of blockbuster anti-diabetic drug Vildagliptin manufactured by the Swiss drugmaker, Novartis, will soon expire on...
Torrent Pharma, Glenmark enter agreement to market Remogliflozin under trademark Zucator in India Medical Dialogues Bureau11 July 2019 10:00 AM IST"Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India," Glenmark Pharma...
Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen Meghna A Singhania30 April 2019 10:16 AM ISTGlenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
Patent Infringement: Cadila Healthcare, two others prohibited from launching Linagliptin Metformin Hydrochloride tablets Meghna A Singhania22 April 2019 2:07 PM ISTAHMEDABAD: In a major setback, three Gujarat based pharmaceutical companies including Cadila Healthcare, West Coast Pharmaceutical Works Ltd and Maan...
Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate Meghna A Singhania31 March 2019 1:39 PM ISTNew Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard...
